<DOC>
	<DOC>NCT00894868</DOC>
	<brief_summary>This study will assess the effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure (NYHA Class I-III). Effect on HbA1c and overall safety and tolerability will also be assessed.</brief_summary>
	<brief_title>Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Patients with T2DM, diagnosed at least 3 months prior to Visit 1 CHF (NYHA Class I, Class II, or Class III) at Visit 1 LVEF &lt; 40% Pregnant or lactating female FPG ≥ 270 mg/dL (≥15 mmol/L)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>CHF, vildagliptin</keyword>
	<keyword>metabolic disease</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>T2DM</keyword>
</DOC>